– Europe’s first oral medication for the treatment of bladder pain syndrome (BPS) characterised by glomerulations or Hunner’s lesions has been approved.
The European Commissionannounced EU approval for elmironR. With theMarketing Authorisation for elmironR, bene-Arzneimittel has Europe’s first approved drug therapy forthe treatment of bladder pain syndrome characterised byeitherglomerulations or Hunner’slesionsin adults with moderate to severe pain,urgency andfrequency of micturition. This disease pattern is also known as interstitial cystitis (IC).
Bladder pain syndrome characterised by glomerulations or Hunner’s lesions (or IC) is a chronic bladder disease accompanied by moderate to severe pain, urgency and frequency of micturition that significantly impairs quality of life.
With bene-Arzneimittel’s newly granted Marketing Authorisation of elmironR the first oral medical product has been approved for treating this disease in the EU. The benefits with elmironR are its ability to relieve pain and urgency as well as to improve overall symptoms of the disease in adults with bladder pain syndrome
Further information can be found here:
elmironR contains the active ingredient pentosan polysulfate sodium (PPS) which is recommended as a drug of choice for the treatment of bladder pain syndrome in the guidelines of the European Association for Urology.
bene-Arzneimittel is looking for local distributors in EU and selected Non-EU countries. Individual requests can be sent to: [email protected].
About bene-Arzneimittel GmbH
bene-Arzneimittel primarily focuses on the treatment of sensitive patient groups within paediatrics, analgesics and urology, with an emphasis on the active ingredients paracetamol and pentosan polysulfate sodium. The mid-sized company develops and produces medicinal products “Made in Germany” and distributes them in Europe and selected countries worldwide. Pentosan polysulfate sodium is produced in Germany and distributed worldwide by the bene group.
Editor and additional information:
PRONOMEN Public Relations und Produktkommunikation GmbH & Co. KG, Cologne
Christine v. Welck, tel.: +44-(0221)-94081228, [email protected]
(Immediapress – Adnkronos
Immediapress e’ un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dall’ente che lo emette. Padovanews non e’ responsabile per i contenuti dei comunicati trasmessi.)